Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
ACTON, Mass. , June 03, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update.
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.
Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds
ACTON, Mass. , April 07, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered.
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass. , Nov. 13, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board.
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
ACTON, Mass. , June 28, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm.
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock.